You are here: MEDICA Portal. MEDICA Magazine. Archive. Cancer.
Tapeworm Drug Inhibits Colon Cancer Metastasis
In Germany alone, there are appro-
ximated 73 000 new cases of the
disease every year; © panther-
media.net / vishnukumar sivaraman
Colon cancer is one of the most common tumor diseases in Western countries. In Germany alone, there are approximated 73 000 new cases of the disease every year. Despite surgery, chemotherapy and radiation therapy, only about half of the affected patients are cured.
The reason is that around 20 percent of the colon cancer patients already have metastases at diagnosis and in about one third of the patients, metastasis occurs despite successful initial treatment. Of these patients with metastatic colon cancer, the five-year survival rate is only about ten percent. By contrast, for nonmetastatic colon cancer patients the survival rate is 90 percent.
Scientists have known for several years that the gene S100A4/metastasin can initiate colon cancer metastasis. Five years ago Stein, working together with Schlag and Professor Walter Birchmeier (MDC), showed how this gene is regulated. They found that the beta-catenin gene, when mutant, activates this S100A4/metastasin gene, thus triggering colon cancer metastasis. Beta-catenin normally regulates cellular adhesion.
The scientists looked for compounds that block the expression of the metastasin gene. They screened 1280 compounds and found what they were looking for: niclosamide, a drug until now approved for use to treat intestinal parasite infections from tapeworms.
Surprisingly, the researchers discovered that niclosamide inhibits the beta catenin-driven expression of the S100A4/metastasin gene, both in the cell culture and in mice. The animals had fewer metastases.
Professor Ulrike Stein, Experimental and Clinical Research Center, Charité/Max Delbrück Center, MDC, Berlin, Germany, made this discovery in collaboration with Professor Robert H. Shoemaker, National Cancer Institute, NCI, Frederick, Maryland, USA. Plans are already underway with Professor Peter M. Schlag, Charité Comprehensive Cancer Center, to conduct a clinical trial. Next, the researchers want to conduct clinical trials to find out whether the compound is also effective in patients with metastasizing colon cancer.
MEDICA.de; Quelle: Max-Delbrück-Centrum für Molekulare Medizin (MDC) Berlin-Buch